Despite the high response rates to anti‐CD30 CAR‐T cells, when preceded by lymphodepleting chemotherapy, disease progression is common, with treatment failures being mainly correlated to higher metabolic tumor volume (> 60 mL) by PET before CAR‐T cell infusion [181]. The gene discussed is TNFRSF8; the disease is neoplasm.